Everence Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Everence Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,984	Closed	-$67	–	780
2022 Q4	$67	Sell	1,984 -1,194	-38%	-$57.8K	0.01%	744
2022 Q3	$153K	Hold	3,178	–	–	0.01%	687
2022 Q2	$181K	Buy	3,178 +1,985	+166%	+$125K	0.02%	669
2022 Q1	$96K	Buy	+1,193	New	+$177K	0.01%	728
2018 Q1	–	Sell	-677	Closed	-$606K	–	435
2017 Q4	$606K	Hold	677	–	–	0.13%	192
2017 Q3	$244K	Hold	677	–	–	0.06%	322
2017 Q2	$198K	Hold	677	–	–	0.05%	353
2017 Q1	$238K	Buy	+677	New	+$152K	0.06%	304

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Everence Capital Management's NKTR Position: Q1 2023 in Review

Everence Capital Management sold out of Nektar Therapeutics (NKTR) in Q1 2023, closing a stake of 1,984 shares — an estimated $67 sold.

Everence Capital Management first reported a position in NKTR in Q1 2017 and held it in 8 quarters. The position peaked at $606K in Q4 2017. 195 funds tracked by Wall St. Rank hold NKTR as of Q1 2023.

Everence Capital Management reported no remaining Nektar Therapeutics position as of Q1 2023 after selling out during the quarter.
Everence Capital Management sold 1,984 Nektar Therapeutics shares in Q1 2023, an estimated $67.
Everence Capital Management first reported a position in Nektar Therapeutics in Q1 2017 and held it in 8 quarters.
Everence Capital Management's Nektar Therapeutics position peaked at $606K in Q4 2017.
195 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2023.

Based on Everence Capital Management's 13F filing for Q1 2023, filed 4 Apr 2023.